NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to provide superior long-term remission for patients with autoimmune diseases – and Allergic Disorders, announced today that it will be attending the Sachs Associates 22nd The annual Biotech in Europe Forum for global partnerships and investments will be held in Basel, Switzerland on September 21-22.
Jonathan Rigby, Chief Executive Officer of the Revolo Group, and Dr. Rely Foulkes, Chief Scientific Officer, will present a company overview on Wednesday, September 21 at 12:00 p.m. CEST (6:00 a.m. EDT). In addition, dr. Foulkes will participate in an expert panel discussion on autoimmune and inflammatory diseases on Thursday, September 22 at 11:10 a.m. CEST (5:10 a.m. EDT).
The Sachs Associates Biotech in Europe Forum is highly transactional and consists of a series of panels and presentations from leading investment, pharmaceutical and biotech companies. The full agenda of the forum can be accessed here.
About Revolo biotherapeutics
Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide, respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that leads to autoimmune or allergic diseases. ‘1805 is a modified analogue of a key protein involved in immune function to be evaluated in a second Phase 2 clinical trial in moderate to severe rheumatoid arthritis and a Phase 2 clinical trial in non-infectious uveitis. ‘1104 is a peptide derived from a natural immunoregulatory protein and has been evaluated in a fully randomized Phase 2 clinical trial for patients with eosinophilic esophagitis (EoE) and a Phase 2 clinical trial for…
